Table of Contents
Chemotherapy Research and Practice
Volume 2012 (2012), Article ID 282570, 11 pages
http://dx.doi.org/10.1155/2012/282570
Review Article

Chemotherapy and Dietary Phytochemical Agents

NGO Praeventio, Näituse 22-3, 50407 Tartu, Estonia

Received 8 October 2012; Revised 23 November 2012; Accepted 29 November 2012

Academic Editor: G. J. Peters

Copyright © 2012 Katrin Sak. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. S. Liu, “Mechanisms of chemotherapeutic drug resistance in cancer therapy—a quick review,” Taiwanese Journal of Obstetrics and Gynecology, vol. 48, no. 3, pp. 239–244, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Osiecki, Cancer: A Nutritional, Biochemical Approach, Bioconcepts Publishing, 2002.
  3. R. E. Maccormick, “Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty?” Medical Hypotheses, vol. 67, no. 2, pp. 212–215, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. J. R. Bertino, “Cancer research: from folate antagonism to molecular targets,” Best Practice & Research: Clinical Haematology, vol. 22, no. 4, pp. 577–582, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. R. M. Howes, “Dangers of antioxidants in cancer patients: a review,” Philica, Article ID 153, 2009. View at Google Scholar
  6. H. Ma, T. Das, S. Pereira et al., “Efficacy of dietary antioxidants combined with a chemotherapeutic agent on human colon cancer progression in a fluorescent orthotopic mouse model,” Anticancer Research, vol. 29, no. 7, pp. 2421–2426, 2009. View at Google Scholar · View at Scopus
  7. J. Sagar, B. Chaib, K. Sales, M. Winslet, and A. Seifalian, “Role of stem cells in cancer therapy and cancer stem cells: a review,” Cancer Cell International, vol. 7, pp. 9–19, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. X. Z. Wu, “A new classification system of anticancer drugs—based on cell biological mechanisms,” Medical Hypotheses, vol. 66, no. 5, pp. 883–887, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. D. W. Lamson and M. S. Brignall, “Antioxidants in cancer therapy; their actions and interactions with oncologic therapies,” Alternative Medicine Review, vol. 4, no. 5, pp. 304–329, 1999. View at Google Scholar · View at Scopus
  10. G. E. Parris, “Clinically significant cancer evolves from transient mutated and/or aneuploid neoplasia by cell fusion to form unstable syncytia that give rise to ecologically viable parasite species,” Medical Hypotheses, vol. 65, no. 5, pp. 846–850, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Harless and Y. Qiu, “Cancer: a medical emergency,” Medical Hypotheses, vol. 67, no. 5, pp. 1054–1059, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Dittmar, C. Nagler, S. Schwitalla, G. Reith, B. Niggemann, and K. S. Zänker, “Recurrence cancer stem cells—made by cell fusion?” Medical Hypotheses, vol. 73, no. 4, pp. 542–547, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Cairns, I. Papandreou, and N. Denko, “Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment,” Molecular Cancer Research, vol. 4, no. 2, pp. 61–70, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. J. E. Trosko and R. J. Ruch, “Gap junctions as targets for cancer chemoprevention and chemotherapy,” Current Drug Targets, vol. 3, no. 6, pp. 465–482, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Myhr, “MR guided cancer treatment system for an elevated therapeutic index—a macroscopic approach,” Medical Hypotheses, vol. 70, no. 3, pp. 665–670, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Ghosh, C. K. Thodeti, A. C. Dudley, A. Mammoto, M. Klagsbrun, and D. E. Ingber, “Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 32, pp. 11305–11310, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Fishman, S. Bar-Yehuda, M. Synowitz et al., “Adenosine receptors and cancer,” Handbook of Experimental Pharmacology, vol. 193, pp. 399–441, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. E. W. LaPensee, T. R. Tuttle, S. R. Fox, and N. Ben-Jonathan, “Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-α-positive and -negative breast cancer cells,” Environmental Health Perspectives, vol. 117, no. 2, pp. 175–180, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. S. W. Lowe, E. Cepero, and G. Evan, “Intrinsic tumour suppression,” Nature, vol. 432, no. 7015, pp. 307–315, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Bansal, M. Jaggi, R. K. Khar, and S. Talegaonkar, “Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 12, no. 1, pp. 46–78, 2009. View at Google Scholar · View at Scopus
  21. D. Y. Lu, X. L. Chen, and J. Ding, “Individualized cancer chemotherapy integrating drug sensitivity tests, pathological profile analysis and computational coordination—an effective strategy to improve clinical treatment,” Medical Hypotheses, vol. 66, no. 1, pp. 45–51, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. D. J. Liska, “The detoxification enzyme systems,” Alternative Medicine Review, vol. 3, no. 3, pp. 187–198, 1998. View at Google Scholar · View at Scopus
  23. C. P. Wu, C. H. Hsieh, and Y. S. Wu, “The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy,” Molecular Pharmaceutics, vol. 8, pp. 1996–2011, 2011. View at Google Scholar
  24. T. Eichhorn and T. Efferth, “P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs,” Journal of Ethnopharmacology, vol. 141, pp. 557–570, 2012. View at Publisher · View at Google Scholar
  25. A. Berruti, M. P. Brizzi, D. Generali et al., “Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions,” Oncologist, vol. 13, no. 11, pp. 1137–1148, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Bonnet, S. L. Archer, J. Allalunis-Turner et al., “A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth,” Cancer Cell, vol. 11, no. 1, pp. 37–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. P. S. Steeg and D. Theodorescu, “Metastasis: a therapeutic target for cancer,” Nature Clinical Practice Oncology, vol. 5, no. 4, pp. 206–219, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. W. Q. Ding, B. Liu, J. L. Vaught, R. D. Palmiter, and S. E. Lind, “Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells,” Molecular Cancer Therapeutics, vol. 5, no. 7, pp. 1864–1872, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Ahmad, S. Banerjee, Z. Wang, D. Kong, A. P. N. Majumdar, and F. H. Sarkar, “Aging and inflammation: etiological culprits of cancer,” Current Aging Science, vol. 2, no. 3, pp. 174–186, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. V. Mongrain and N. Cermakian, “Clock genes in health and diseases,” Journal of Applied Biomedicine, vol. 7, no. 1, pp. 15–33, 2009. View at Google Scholar · View at Scopus
  31. E. Haus, “Chronobiology in oncology,” International Journal of Radiation Oncology, Biology, Physics, vol. 73, no. 1, pp. 3–5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Y. Gorbacheva, R. V. Kondratov, R. Zhang et al., “Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 9, pp. 3407–3412, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Sajan, T. A. Cinu, A. J. Chacko, J. Litty, and T. Jaseeda, “Chronotherapeutics and chronotherapeutic drug delivery systems,” Tropical Journal of Pharmaceutical Research, vol. 8, no. 5, pp. 467–475, 2009. View at Google Scholar · View at Scopus
  34. T. C. Erren, “Could visible light contribute to the development of leukaemia and other cancers in children?” Medical Hypotheses, vol. 64, no. 4, pp. 864–871, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Sahar and P. Sassone-Corsi, “Metabolism and cancer: the circadian clock connection,” Nature Reviews Cancer, vol. 9, no. 12, pp. 886–896, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Lévi, E. Filipski, I. Iurisci, X. M. Li, and P. Innominato, “Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 72, pp. 465–475, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. P. Antoch, R. V. Kondratov, and J. S. Takahashi, “Circadian clock genes as modulators of sensitivity to genotoxic stress,” Cell Cycle, vol. 4, no. 7, pp. 901–907, 2005. View at Google Scholar · View at Scopus
  38. G. Gebauer, “On the way to specifically targeting minimal residual disease?” Breast Cancer Research, vol. 10, no. 5, article 112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Zhou, P. Zou, Z. C. Chen, and Y. You, “A novel vicious cycle cascade in tumor chemotherapy,” Medical Hypotheses, vol. 69, no. 6, pp. 1230–1233, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. T. A. Ahles and A. J. Saykin, “Candidate mechanisms for chemotherapy-induced cognitive changes,” Nature Reviews Cancer, vol. 7, no. 3, pp. 192–201, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Han, Y. M. Yang, J. Dietrich, A. Luebke, M. Mayer-Pröschel, and M. Noble, “Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system,” Journal of Biology, vol. 7, no. 4, pp. 12–33, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. G. L. Nicolson, “Lipid replacement/antioxidant therapy as an adjunct supplement to reduce the adverse effects of cancer therapy and restore mitochondrial function,” Pathology and Oncology Research, vol. 11, no. 3, pp. 139–144, 2005. View at Google Scholar · View at Scopus
  43. C. Constantinou, A. Papas, and A. I. Constantinou, “Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs,” International Journal of Cancer, vol. 123, no. 4, pp. 739–752, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. R. W. Johnstone, A. A. Ruefli, and S. W. Lowe, “Apoptosis: a link between cancer genetics and chemotherapy,” Cell, vol. 108, no. 2, pp. 153–164, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Kovacic, “Unifying mechanism for anticancer agents involving electron transfer and oxidative stress: clinical implications,” Medical Hypotheses, vol. 69, no. 3, pp. 510–516, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. C. L. Loprinzi, D. L. Barton, A. Jatoi et al., “Symptom control trials: a 20-year experience,” Journal of Supportive Oncology, vol. 5, no. 3, pp. 119–128, 2007. View at Google Scholar · View at Scopus
  47. B. U. Philips, The Case for Cancer Nutritional Support, The Cancer Nutrition Network of Texas, 1999.
  48. K. N. Prasad, W. C. Cole, B. Kumar, and K. C. Prasad, “Scientific rationale for using high-dose multiple micronutrients as an adjunct to standard and experimental cancer therapies,” Journal of the American College of Nutrition, vol. 20, no. 5, pp. 450S–463S, 2001. View at Google Scholar · View at Scopus
  49. A. Montazeri, “Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007,” Journal of Experimental and Clinical Cancer Research, vol. 27, no. 1, pp. 32–62, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Al-Tonbary, M. Al-Haggar, R. El-Ashry, S. El-Dakroory, H. Azzam, and A. Fouda, “Vitamin E and N-acetylcysteine as antioxidant adjuvant therapy in children with acute lymphoblastic leukemia,” Advances in Hematology, vol. 2009, Article ID 689639, 5 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. J. J. Kim and I. F. Tannock, “Repopulation of cancer cells during therapy: an important cause of treatment failure,” Nature Reviews Cancer, vol. 5, no. 7, pp. 516–525, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. G. L. Semenza, “Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics,” Oncogene, vol. 29, no. 5, pp. 625–634, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. A. B. Csoka and M. Szyf, “Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology,” Medical Hypotheses, vol. 73, no. 5, pp. 770–780, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Dietrich, R. Han, Y. Yang, M. Mayer-Pröschel, and M. Noble, “CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo,” Journal of Biology, vol. 5, pp. 22–44, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. G. E. Jackson, “Chemo brain—a psychotropic drug phenomenon?” Medical Hypotheses, vol. 70, no. 3, pp. 572–577, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Balducci and W. B. Ershler, “Cancer and ageing: a nexus at several levels,” Nature Reviews Cancer, vol. 5, no. 8, pp. 655–662, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Feres, J. I. Salluh, C. Ferreira, and M. Soares, “Severe acute tumor lysis syndrome in patients with germ-cell tumors,” Indian Journal of Urology, vol. 24, no. 4, pp. 555–557, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Hochberg and M. S. Cairo, “Tumor lysis syndrome: current perspective,” Haematologica, vol. 93, no. 1, pp. 9–13, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. B. Brom, “The antioxidant controversy and cancer,” South African Family Practice, vol. 51, no. 2, p. 119, 2009. View at Google Scholar · View at Scopus
  60. S. M. Sagar, D. Yance, and R. K. Wong, “Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer—part 2,” Current Oncology, vol. 13, no. 3, pp. 99–107, 2006. View at Google Scholar · View at Scopus
  61. C. D. Davis, “Nutritional interactions: credentialing of molecular targets for cancer prevention,” Experimental Biology and Medicine, vol. 232, no. 2, pp. 176–183, 2007. View at Google Scholar · View at Scopus
  62. B. Jung and N. Ahmad, “Melatonin in cancer management: progress and promise,” Cancer Research, vol. 66, no. 20, pp. 9789–9793, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. C. Z. Wang and C. S. Yuan, “Potential role of Ginseng in the treatment of colorectal cancer,” American Journal of Chinese Medicine, vol. 36, no. 6, pp. 1019–1028, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. H. H. Aung, S. R. Mehendale, C. Z. Wang, J. T. Xie, E. McEntee, and C. S. Yuan, “Cisplatin's tumoricidal effect on human breast carcinoma MCF-7 cells was not attenuated by American ginseng,” Cancer Chemotherapy and Pharmacology, vol. 59, no. 3, pp. 369–374, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Z. Wang, X. Luo, B. Zhang et al., “Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells,” Cancer Chemotherapy and Pharmacology, vol. 60, no. 1, pp. 69–79, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. S. M. Sagar, D. Yance, and R. K. Wong, “Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer—part 1,” Current Oncology, vol. 13, no. 1, pp. 14–26, 2006. View at Google Scholar · View at Scopus
  67. S. Sen, H. Sharma, and N. Singh, “Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway,” Biochemical and Biophysical Research Communications, vol. 331, no. 4, pp. 1245–1252, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. D. W. Lamson and M. S. Brignall, “Antioxidants and cancer therapy II: quick reference guide,” Alternative Medicine Review, vol. 5, no. 2, pp. 152–163, 2000. View at Google Scholar · View at Scopus
  69. Y. Sadzuka, T. Sugiyama, and S. Hirota, “Modulation of cancer chemotherapy by green tea,” Clinical Cancer Research, vol. 4, no. 1, pp. 153–156, 1998. View at Google Scholar · View at Scopus
  70. T. Sugiyama and Y. Sadzuka, “Enhancing effects of green tea components on the antitumor activity of adriamycin against M5076 ovarian sarcoma,” Cancer Letters, vol. 133, no. 1, pp. 19–26, 1998. View at Publisher · View at Google Scholar · View at Scopus
  71. D. W. Lamson and M. S. Brignall, “Antioxidants and cancer III: quercetin,” Alternative Medicine Review, vol. 5, no. 3, pp. 196–208, 2000. View at Google Scholar · View at Scopus
  72. G. Scambia, F. O. Ranelletti, P. B. Panici et al., “Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target,” Cancer Chemotherapy and Pharmacology, vol. 34, no. 6, pp. 459–464, 1994. View at Publisher · View at Google Scholar · View at Scopus
  73. R. Hoffman, L. Graham, and E. S. Newlands, “Enhanced anti-proliferative action of busulphan by quercetin on the human leukaemia cell line K562,” British Journal of Cancer, vol. 59, no. 3, pp. 347–348, 1989. View at Google Scholar · View at Scopus
  74. Y. H. Ju, D. R. Doerge, K. F. Allred, C. D. Allred, and W. G. Helferich, “Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice,” Cancer Research, vol. 62, no. 9, pp. 2474–2477, 2002. View at Google Scholar · View at Scopus
  75. A. I. Constantinou, B. E. P. White, D. Tonetti et al., “The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours,” European Journal of Cancer, vol. 41, no. 4, pp. 647–654, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. F. Shen, X. Xue, and G. Weber, “Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells,” Anticancer Research, vol. 19, no. 3, pp. 1657–1662, 1999. View at Google Scholar · View at Scopus
  77. M. E. Bracke, H. T. Depypere, T. Boterberg et al., “Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer,” Journal of the National Cancer Institute, vol. 91, no. 4, pp. 354–359, 1999. View at Google Scholar · View at Scopus
  78. H. Wang, D. Peng, and J. Xie, “Ginseng leaf-stem: bioactive constituents and pharmacological functions,” Chinese Medicine, vol. 4, pp. 20–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. Q. H. Zhang, C. F. Wu, L. Duan, and J. Y. Yang, “Protective effects of total saponins from stem and leaf of Panax ginseng against cyclophosphamide-induced genotoxicity and apoptosis in mouse bone marrow cells and peripheral lymphocyte cells,” Food and Chemical Toxicology, vol. 46, no. 1, pp. 293–302, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Mehendale, H. Aung, A. Wang et al., “American ginseng berry extract and ginsenoside Re attenuate cisplatin-induced kaolin intake in rats,” Cancer Chemotherapy and Pharmacology, vol. 56, no. 1, pp. 63–69, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. M. K. Kuhlmann, E. Horsch, G. Burkhardt, M. Wagner, and H. Köhler, “Reduction of cisplatin toxicity in cultured renal tubular cells by the bioflavonoid quercetin,” Archives of Toxicology, vol. 72, no. 8, pp. 536–540, 1998. View at Publisher · View at Google Scholar · View at Scopus
  82. W. W. G. Jia, X. Bu, D. Philips et al., “Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy,” Canadian Journal of Physiology and Pharmacology, vol. 82, no. 7, pp. 431–437, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. S. Kitagawa, T. Nabekura, and S. Kamiyama, “Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells,” Journal of Pharmacy and Pharmacology, vol. 56, no. 8, pp. 1001–1005, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. L. C. Lin, M. N. Wang, and T. H. Tsai, “Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38,” Chemico-Biological Interactions, vol. 174, no. 3, pp. 177–182, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. T. Ikegawa, H. Ohtani, N. Koyabu et al., “Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells,” Cancer Letters, vol. 177, no. 1, pp. 89–93, 2002. View at Publisher · View at Google Scholar · View at Scopus
  86. S. C. Shin, J. S. Choi, and X. Li, “Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats,” International Journal of Pharmaceutics, vol. 313, no. 1-2, pp. 144–149, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. J. S. Choi, B. W. Jo, and Y. C. Kim, “Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 57, no. 2, pp. 313–318, 2004. View at Publisher · View at Google Scholar · View at Scopus
  88. G. Sliutz, J. Karlseder, C. Tempfer, L. Orel, G. Holzer, and M. M. Simon, “Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy,” British Journal of Cancer, vol. 74, no. 2, pp. 172–177, 1996. View at Google Scholar · View at Scopus
  89. X. Li and J. S. Choi, “Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats,” International Journal of Pharmaceutics, vol. 337, no. 1-2, pp. 188–193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. W. Wätjen, G. Michels, B. Steffan et al., “Low concentrations of flavonoids are protective in rat H4IIE cells whereas high concentrations cause DNA damage and apoptosis,” Journal of Nutrition, vol. 135, no. 3, pp. 525–531, 2005. View at Google Scholar · View at Scopus
  91. A. D. Smith, Y. I. Kim, and H. Refsum, “Is folic acid good for everyone?” American Journal of Clinical Nutrition, vol. 87, no. 3, pp. 517–533, 2008. View at Google Scholar · View at Scopus
  92. J. Neuzil, M. Tomasetti, Y. Zhao et al., “Vitamin E analogs, a novel group of “mitocans,” as anticancer agents: the importance of being redox-silent,” Molecular Pharmacology, vol. 71, no. 5, pp. 1185–1199, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. K. N. Prasad, B. Kumar, X. D. Yan, A. J. Hanson, and W. C. Cole, “α-tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review,” Journal of the American College of Nutrition, vol. 22, no. 2, pp. 108–117, 2003. View at Google Scholar · View at Scopus
  94. D. W. Lamson and S. M. Plaza, “The anticancer effects of vitamin K,” Alternative Medicine Review, vol. 8, no. 3, pp. 303–318, 2003. View at Google Scholar · View at Scopus
  95. S. Matzno, Y. Yamaguchi, T. Akiyoshi, T. Nakabayashi, and K. Matsuyama, “An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents,” Biological and Pharmaceutical Bulletin, vol. 31, no. 6, pp. 1270–1273, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. L. Pinto, A. Sloan, I. Persaud, and N. R. Narain, “Normalization of BCL-2 family members in breast cancer by coenzyme Q10,” Ethnicity & Disease, vol. 19, pp. S3-17–S3-18, 2009. View at Google Scholar
  97. G. M. D'Andrea, “Use of antioxidants during chemotherapy and radiotherapy should be avoided,” CA: A Cancer Journal for Clinicians, vol. 55, no. 5, pp. 319–321, 2005. View at Google Scholar · View at Scopus
  98. B. D. Lawenda, K. M. Kelly, E. J. Ladas, S. M. Sagar, A. Vickers, and J. B. Blumberg, “Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?” Journal of the National Cancer Institute, vol. 100, no. 11, pp. 773–783, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. R. I. Salganik, “The benefits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population,” Journal of the American College of Nutrition, vol. 20, no. 5, pp. 464S–472S, 2001. View at Google Scholar · View at Scopus
  100. J. R. DiPalma and R. McMichael, “The interaction of vitamins with cancer chemotherapy,” CA: A Cancer Journal for Clinicians, vol. 29, no. 5, pp. 280–286, 1979. View at Google Scholar · View at Scopus
  101. C. B. Simone and C. B. Simone II, “Re: should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?” Journal of the National Cancer Institute, vol. 100, no. 21, pp. 1558–1559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. G. Manda, M. T. Nechifor, and T. M. Neagu, “Reactive oxygen species, cancer and anti-cancer therapies,” Current Chemical Biology, vol. 3, no. 1, pp. 22–46, 2009. View at Google Scholar · View at Scopus
  103. K. N. Prasad and W. C. Cole, “Antioxidants in cancer therapy,” Journal of Clinical Oncology, vol. 24, pp. e8–e9, 2006. View at Google Scholar
  104. L. G. Hersoug and J. Arnau, “A built-in co-carcinogenic effect due to viruses involved in latent or persistent infections,” Medical Hypotheses, vol. 68, no. 5, pp. 1001–1008, 2007. View at Publisher · View at Google Scholar · View at Scopus